Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study

Jens Benn Sørensen; Pia Horvat; Mats Rosenlund; Anne Mette Kejs; Dony Patel; Ariadna Juarez-Garcia; Laure Lacoin; Melinda J Daumont; John R Penrod; John C O'Donnell; Odd Terje Brustugun; Simon Ekman

doi:10.2217/fon-2021-0746

Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study

Jens Benn Sørensen^*, Pia Horvat, Mats Rosenlund, Anne Mette Kejs, Dony Patel, Ariadna Juarez-Garcia, Laure Lacoin, Melinda J Daumont, John R Penrod, John C O'Donnell, Odd Terje Brustugun, Simon Ekman

^*Corresponding author af dette arbejde

Afdeling for Kræftbehandling

6 Citationer (Scopus)

Abstract

Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/IIIA and IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous NSCLC (53.0-60.6%) but not squamous NSCLC (44.9-47.3%). 1-year OS improved in patients with stage IV non-squamous NSCLC (23-31%) but not squamous NSCLC (22-25%). Conclusion: Trends indicated improved OS as treatments evolved between 2005 and 2015, but the effect was limited to 1-year OS in stage IV disease.

Originalsprog	Engelsk
Tidsskrift	Future oncology (London, England)
Vol/bind	18
Udgave nummer	2
Sider (fra-til)	205-214
Antal sider	10
ISSN	1479-6694
DOI	https://doi.org/10.2217/fon-2021-0746
Status	Udgivet - jan. 2022

Adgang til dokumentet

10.2217/fon-2021-0746

Andre filer og links

Link to publication in Scopus

Citationsformater

Sørensen, J. B., Horvat, P., Rosenlund, M., Kejs, A. M., Patel, D., Juarez-Garcia, A., Lacoin, L., Daumont, M. J., Penrod, J. R., O'Donnell, J. C., Brustugun, O. T., & Ekman, S. (2022). Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study. Future oncology (London, England), 18(2), 205-214. https://doi.org/10.2217/fon-2021-0746

Sørensen, JB, Horvat, P, Rosenlund, M, Kejs, AM, Patel, D, Juarez-Garcia, A, Lacoin, L, Daumont, MJ, Penrod, JR, O'Donnell, JC, Brustugun, OT & Ekman, S 2022, 'Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study', Future oncology (London, England), bind 18, nr. 2, s. 205-214. https://doi.org/10.2217/fon-2021-0746

@article{9d127e84bc704ed3914918629b67ad80,

title = "Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study",

abstract = "Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/IIIA and IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous NSCLC (53.0-60.6%) but not squamous NSCLC (44.9-47.3%). 1-year OS improved in patients with stage IV non-squamous NSCLC (23-31%) but not squamous NSCLC (22-25%). Conclusion: Trends indicated improved OS as treatments evolved between 2005 and 2015, but the effect was limited to 1-year OS in stage IV disease.",

keywords = "Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Non-Small-Cell Lung/diagnosis, Chemoradiotherapy, Adjuvant/methods, Denmark/epidemiology, Female, Follow-Up Studies, History, 21st Century, Humans, Lung Neoplasms/diagnosis, Lung/pathology, Male, Middle Aged, Mortality/history, Neoadjuvant Therapy/methods, Neoplasm Staging, Pneumonectomy/statistics & numerical data, Retrospective Studies, Treatment Outcome, Young Adult",

author = "S{\o}rensen, {Jens Benn} and Pia Horvat and Mats Rosenlund and Kejs, {Anne Mette} and Dony Patel and Ariadna Juarez-Garcia and Laure Lacoin and Daumont, {Melinda J} and Penrod, {John R} and O'Donnell, {John C} and Brustugun, {Odd Terje} and Simon Ekman",

year = "2022",

month = jan,

doi = "10.2217/fon-2021-0746",

language = "English",

volume = "18",

pages = "205--214",

journal = "Future oncology (London, England)",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015)

T2 - SCAN-LEAF study

AU - Sørensen, Jens Benn

AU - Horvat, Pia

AU - Rosenlund, Mats

AU - Kejs, Anne Mette

AU - Patel, Dony

AU - Juarez-Garcia, Ariadna

AU - Lacoin, Laure

AU - Daumont, Melinda J

AU - Penrod, John R

AU - O'Donnell, John C

AU - Brustugun, Odd Terje

AU - Ekman, Simon

PY - 2022/1

Y1 - 2022/1

N2 - Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/IIIA and IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous NSCLC (53.0-60.6%) but not squamous NSCLC (44.9-47.3%). 1-year OS improved in patients with stage IV non-squamous NSCLC (23-31%) but not squamous NSCLC (22-25%). Conclusion: Trends indicated improved OS as treatments evolved between 2005 and 2015, but the effect was limited to 1-year OS in stage IV disease.

AB - Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagnosed with incident NSCLC (2005-2015; follow-up: 2016). Initial treatments and overall survival (OS) are reported. Results: 31,939 NSCLC patients (51.6% stage IV) were included. Increasing use of curative radiotherapy/chemoradiation for stage I, II/IIIA and IIIB NSCLC coincided with improved 2-year OS. Systemic anticancer therapy use increased for patients with stage IV non-squamous NSCLC (53.0-60.6%) but not squamous NSCLC (44.9-47.3%). 1-year OS improved in patients with stage IV non-squamous NSCLC (23-31%) but not squamous NSCLC (22-25%). Conclusion: Trends indicated improved OS as treatments evolved between 2005 and 2015, but the effect was limited to 1-year OS in stage IV disease.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Carcinoma, Non-Small-Cell Lung/diagnosis

KW - Chemoradiotherapy, Adjuvant/methods

KW - Denmark/epidemiology

KW - Female

KW - Follow-Up Studies

KW - History, 21st Century

KW - Humans

KW - Lung Neoplasms/diagnosis

KW - Lung/pathology

KW - Male

KW - Middle Aged

KW - Mortality/history

KW - Neoadjuvant Therapy/methods

KW - Neoplasm Staging

KW - Pneumonectomy/statistics & numerical data

KW - Retrospective Studies

KW - Treatment Outcome

KW - Young Adult

UR - http://www.scopus.com/inward/record.url?scp=85121582602&partnerID=8YFLogxK

U2 - 10.2217/fon-2021-0746

DO - 10.2217/fon-2021-0746

M3 - Journal article

C2 - 34784783

SN - 1479-6694

VL - 18

SP - 205

EP - 214

JO - Future oncology (London, England)

JF - Future oncology (London, England)

IS - 2

ER -

Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater